Acepodia Enters Strategic Clinical Collaboration with Pfizer to Accelerate Development of Antibody-Cell Conjugation-Based Cell Therapies in Autoimmune Diseases | The Manila Times

Through Pfizer Ignite, Acepodia will gain access to Pfizer's resources, scale and expertise as the company broadens the application of its platform beyond oncology into autoimmune diseases
Pfizer Ignite will also provide strategic advisory support for Acepodia's ongoing clinical programs, ACE1831 in NHL and ACE2016 in solid tumors
Acepodia's lead ACC platform therapy has shown clinical benefits in oncology without the limitations of current CAR-T cell therapies

ALAMEDA, Calif. and TAIPEI, Sept. 4, 2024 /PRNewswire/ -- Acepodia (6976:TT), a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) and allogeneic gamma delta 2 (γδ2) T cell platforms, announced today that it has entered a strategic clinical collaboration with Pfizer Ignite to support the development of its therapies in autoimmune diseases. Pfizer Ignite is an end-to-end offering that leverages Pfizer's significant resources, scale, and expertise, alongside a proven track record in the development of breakthroughs, to support biotechs seeking to accelerate their innovations from preclinical R&D through the development lifecycle. Under this new agreement, Pfizer Ignite will provide strategic guidance and resources to Acepodia as the company develops its cell therapies for oncology and autoimmune diseases.

Acepodia's ACC platform, which uses bioorthogonal chemistry and is based on the pioneering work of 2022 Nobel laureate Dr. Carolyn Bertozzi, who applied click chemistry to living systems, creates an off-the-shelf, non-genetically engineered version of CAR-T cell therapy that is more easily scaled and avoids cytokine release storms, neurotoxicity, and other side effects associated with CAR-T cell therapies. Acepodia's lead clinical candidate, ACE1831, is currently being evaluated in a Phase 1 first-in-human clinical trial for patients with non-Hodgkin's lymphoma and has demonstrated a robust and durable effect after a single treatment at the lowest dose.